This is News Broadcast Room of CHEARS.
Our purpose is to create awareness among general public through the various health news updates and interventional updates from the sector of healthcare. This News Room works under Dr. Keerthana Ramesh, Chief Editor, Department of CNAR, CHEAARS.

Novel Drug Approvals for 2020

1 . Gemtesa

Approval Date : 2020-12-23

Active Ingredient: vibegron

Indication : To treat overactive bladder

-----------------------

2 . Ebanga

Approval Date : 2020-12-21

Active Ingredient: ansuvimab-zykl

Indication : To treat ebola

-----------------------

3 . Orgovyx

Approval Date : 2020-12-18

Active Ingredient: relugolix

Indication : To treat advanced prostate cancer

-----------------------

4 . Margenza

Approval Date : 2020-12-16

Active Ingredient: margetuximab (anti-HER2 mAb

Indication : To treat HER2+ breast cancer

-----------------------

5 . Klisyri

Approval Date : 2020-12-14

Active Ingredient: tirbanibulin

Indication : To treat actinic Keratosis of the face or scalp

-----------------------

6 . Orladeyo

Approval Date : 2020-12-03

Active Ingredient: berotralstat

Indication : To treat patients with hereditary angioedema

-----------------------

7 . Gallium 68 PSMA-11

Approval Date : 2020-12-01

Active Ingredient: Gallium 68 PSMA-11

Indication : For detection and localization of prostate cancer

-----------------------

8 . Danyelza

Approval Date : 2020-11-25

Active Ingredient: naxitamab-gqgk

Indication : To treat high-risk refractory or relapsed neuroblastoma

-----------------------

9 . Imcivree

Approval Date : 2020-11-25

Active Ingredient: setmelanotide

Indication : To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency, a rare disorder that causes severe obesity that begins at an early age

-----------------------

10 . Oxlumo

Approval Date : 2020-11-23

Active Ingredient: lumasiran

Indication : To treat hyperoxaluria type 1

-----------------------

11 . Zokinvy

Approval Date : 2020-11-20

Active Ingredient: lonafarnib

Indication : To treat rare conditions related to premature aging

-----------------------

12 . Veklury

Approval Date : 2020-10-22

Active Ingredient: remdesivir

Indication : To treat COVID-19

-----------------------

13 . Inmazeb

Approval Date : 2020-10-14

Active Ingredient: atoltivimab, maftivimab, and odesivimab-ebgn

Indication : To treat ebola virus

-----------------------

14 . Gavreto

Approval Date : 2020-09-04

Active Ingredient: pralsetinib

Indication : To treat non-small lung cancer

-----------------------

15 . Detectnet

Approval Date : 2020-09-03

Active Ingredient: copper Cu 64 dotatate injection

Indication : To help detect certain types of neuroendocrine tumors

-----------------------

16 . Sogroya

Approval Date : 2020-08-28

Active Ingredient: somapacitan-beco

Indication : Growth hormone

-----------------------

17 . Winlevi

Approval Date : 2020-08-26

Active Ingredient: clascoterone

Indication : To treat acne

-----------------------

18 . Enspryng

Approval Date : 2020-08-14

Active Ingredient: satralizumab-mwge

Indication : To treat neuromyelitis optica spectrum disorder

-----------------------

19 . Viltepso

Approval Date : 2020-08-12

Active Ingredient: viltolarsen

Indication : To treat Duchenne muscular dystrophy

-----------------------

20 . Olinvyk

Approval Date : 2020-08-07

Active Ingredient: oliceridine

Indication : To manage acute pain in certain adults

-----------------------

21 . Evrysdi

Approval Date : 2020-08-07

Active Ingredient: risdiplam

Indication : To treat spinal muscular atrophy

-----------------------

22 . Lampit

Approval Date : 2020-08-06

Active Ingredient: nifurtimox

Indication : To treat Chagas disease in certain pediatric patients younger than age 18

-----------------------

23 . Blenrep

Approval Date : 2020-08-05

Active Ingredient: belantamab mafodotin-blmf

Indication : To treat multiple myeloma

-----------------------

24 . Monjuvi

Approval Date : 2020-07-31

Active Ingredient: tafasitamab-cxix

Indication : To treat relapsed or refractory diffuse large B-cell lymphoma

-----------------------

25 . Xeglyze

Approval Date : 2020-07-24

Active Ingredient: abametapir

Indication : To treat head lice

-----------------------

26 . Inqovi

Approval Date : 2020-07-07

Active Ingredient: decitabine and cedazuridine

Indication : To treat adult patients with myelodysplastic syndromes

-----------------------

27 . Rukobia

Approval Date : 2020-07-02

Active Ingredient: fostemsavir

Indication : To treat HIV

-----------------------

28 . Byfavo

Approval Date : 2020-07-02

Active Ingredient: remimazolam

Indication : For sedation

-----------------------

29 . Dojolvi

Approval Date : 2020-06-30

Active Ingredient: triheptanoin

Indication : To treat molecularly long-chain fatty acid oxidation disorders

-----------------------

30 . Zepzelca

Approval Date : 2020-06-15

Active Ingredient: lurbinectedin

Indication : To treat metastatic small cell lung cancer

-----------------------

31 . Uplizna

Approval Date : 2020-06-11

Active Ingredient: inebilizumab-cdon

Indication : To treat neuromyelitis optica spectrum disorder

-----------------------

32 . Tauvid

Approval Date : 2020-05-28

Active Ingredient: flortaucipir F18

Indication : Diagnostic agent for patients with Alzheimer’s disease

-----------------------

33 . Artesunate

Approval Date : 2020-05-26

Active Ingredient: artesunate

Indication : To treat severe malaria

-----------------------

34 . Cerianna

Approval Date : 2020-05-20

Active Ingredient: fluoroestradiol F18

Indication : Diagnostic imaging agent for certain patients with breast cancer

-----------------------

35 . Qinlock

Approval Date : 2020-05-15

Active Ingredient: ripretinib

Indication : To treat advanced gastrointestinal-stromal tumors

-----------------------

36 . Retevmo

Approval Date : 2020-05-08

Active Ingredient: selpercatinib

Indication : To treat lung and thyroid cancers

-----------------------

37 . Tabrecta

Approval Date : 2020-05-06

Active Ingredient: capmatinib

Indication : To treat patients with non small cell lung cancer

-----------------------

38 . Ongentys

Approval Date : 2020-04-24

Active Ingredient: opicapone

Indication : To treat patients with Parkinson’s disease experiencing “off” episodes

-----------------------

39 . Trodelvy

Approval Date : 2020-04-22

Active Ingredient: sacituzumab govitecan-hziy

Indication : To treat adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease

-----------------------

40 . Pemazyre

Approval Date : 2020-04-17

Active Ingredient: pemigatinib

Indication : To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts

-----------------------

41 . Tukysa

Approval Date : 2020-04-17

Active Ingredient: tucatinib

Indication : To treat advanced unresectable or metastatic HER2-positive breast cancer

-----------------------

42 . Koselugo

Approval Date : 2020-04-10

Active Ingredient: selumetinib

Indication : To treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves

-----------------------

43 . Zeposia

Approval Date : 2020-03-25

Active Ingredient: ozanimod

Indication : To treat relapsing forms of multiple sclerosis

-----------------------

44 . Isturisa

Approval Date : 2020-03-06

Active Ingredient: osilodrostat

Indication : To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease

-----------------------

45 . Sarclisa

Approval Date : 2020-03-02

Active Ingredient: isatuximab

Indication : To treat multiple myloma

-----------------------

46 . Nurtec ODT

Approval Date : 2020-02-27

Active Ingredient: rimegepant

Indication : To treat migraine

-----------------------

47 . Barhemsys

Approval Date : 2020-02-26

Active Ingredient: amisulpride

Indication : To help prevent nausea and vomiting after surgery

-----------------------

48 . Vyepti

Approval Date : 2020-02-21

Active Ingredient: eptinezumab-jjmr

Indication : For the preventive treatment of migraine in adults

-----------------------

49 . Nexletol

Approval Date : 2020-02-21

Active Ingredient: bempedoic acid

Indication : To treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C

-----------------------

50 . Pizensy

Approval Date : 2020-02-12

Active Ingredient: lactitol

Indication : To treat chronic idiopathic constipation (CIC) in adults

-----------------------

51 . Tazverik

Approval Date : 2020-01-23

Active Ingredient: tazemetostat

Indication : To treat epithelioid sarcoma

-----------------------

52 . Tepezza

Approval Date : 2020-01-21

Active Ingredient: teprotumumab-trbw

Indication : To treat Thyroid eye disease

-----------------------

53 . Ayvakit

Approval Date : 2020-01-09

Active Ingredient: avapritinib

Indication : To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST)

-----------------------

67
It will be great, if you share your view on above write-up. 
 Combination for Treating Mesothelioma Approved

CHEARS News Room

Combination for Treating Mesothelioma Approved

COVID-19 and its impact on snakebite care in India: a bane or a boon?

CHEARS News Room

COVID-19 and its impact on snakebite care in India: a bane or a boon?

Eli Lilly antibody trial paused over safety concern

CHEARS News Room

Eli Lilly antibody trial paused over safety concern

Admin Login by RSP

Admin Login by Center Team

Dear Visitors !

Articles written by authors are their views and their presentation of ideas and knowledge. CHEARS does not claim right on write-up and authors are the real owner and are responsible for their write-up or views. Posts from CHEARS News Room are interpretations or presentation of news from various news resources. 

Posts from executive committee members are posts from CHEARS Office.  

© Copyright CHEARS

© Center for Health Education, Awareness Resources and Services

Subscribe to Our Newsletter